← All trials
NCT07000084
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 17, 2025
- Primary completion
- Jun 5, 2028
- Completion date
- Dec 5, 2028
- First posted
- May 31, 2025
- Last posted
- Nov 5, 2025
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Official
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.